"As we focus on leveraging the unique characteristics of ACCURINS® to create novel ligand-payload combinations, their ability to encapsulate and control the release kinetics of diverse payloads will play a critical role," said Andrew Hirsch, BIND's president and chief executive officer. "This article highlights BIND's deep expertise in nanomedicine development and our ability to work with collaborators like AstraZeneca to develop new therapies with the capabilities of our ACCURINS® platform. These methods provide a clear view of the broad potential of our technology for new applications that we are leveraging to accelerate our innovative medicine portfolio."About BIND TherapeuticsBIND Therapeutics is a biotechnology company developing novel targeted therapeutics, primarily for the treatment of cancer. BIND'S product candidates are based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. BIND is developing ACCURINS® with three different therapeutic objectives, both through internal research programs and with collaborators: Innovative medicines; enabling potent pathway inhibitors; and differentiated efficacy with approved drugs. BIND's internal discovery efforts are focused on designing oligonucleotide and immune-oncology-based ACCURINS®. BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck & Co., or Merck (known as Merck Sharp & Dohme outside the United States and Canada), Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals), Synergy Pharmaceuticals, PeptiDream and Affilogic to develop ACCURINS® based on their proprietary therapeutic payloads and/or targeting ligands. BIND's collaboration with AstraZeneca has resulted in the Aurora B Kinase inhibitor Accurin AZD2811, which became the second Accurin candidate to enter clinical development. BIND's collaboration with Pfizer has resulted in the selection of an Accurin candidate that is entering IND-enabling studies. For more information, please visit the Company's web site at www.bindtherapeutics.com. Forward-Looking Statements DisclaimerThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential of ACCURINS® to control release kinetics and provide increased concentration of AZD2811 at tumor sites, and potential effects of this process; the potential to leverage of the unique characteristics of our ACCURIN platform; expectations regarding the expansion of payloads that are compatible with our ACCURIN platform; beliefs regarding the data published in the May 10, 2016 issue of the Journal of Controlled Release; and expectations regarding our collaborations with Pfizer, AstraZeneca, F. Hoffmann-La Roche Ltd., Merck, Macrophage, PeptiDream, Synergy and Affilogic. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause BIND's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: risks relating to our recent Chapter 11 filing and our potential delisting from The Nasdaq Stock Market; the fact that the Company may not be successful in consummating any of the strategic or financing alternatives it is exploring; the fact that the Company has incurred significant losses since its inception and expects to incur losses for the foreseeable future; the Company's need for additional funding, which may not be available, in order to continue as a going concern; effects of adverse capital market conditions on the Company's liquidity; adverse effects on the Company's business due to the report of its independent registered public accounting firm on its financial statements for the year ended December 31, 2015, which contains an explanatory paragraph regarding the Company's ability to continue as a going concern; raising additional capital may cause dilution to its stockholders, restrict its operations or require it to relinquish rights to its technologies or drug candidates; the Company's limited operating history; limitations on the Company's ability to utilize net operating loss carryforwards and certain other tax attributes; failure to use and expand its MEDICINAL ENGINEERING® platform to build a pipeline of drug candidates and develop marketable drugs; the early stage of the Company's development efforts with only BIND-014 and Accurin AZD2811 in clinical development; failure of the Company or its collaborators to successfully develop and commercialize drug candidates; clinical drug development involves a lengthy and expensive process, with an uncertain outcome; delays or difficulties in the enrollment of patients in clinical trials; serious adverse or unacceptable side effects or limited efficacy observed during the development of the Company's drug candidates; inability to maintain any of the Company's collaborations, or the failure of these collaborations; inability to enter into a collaboration for BIND-014; the Company's reliance on third parties to conduct its clinical trials and manufacture its drug candidates; the Company's inability to obtain required regulatory approvals; the fact that a fast track or breakthrough therapy designation by the FDA for the Company's drug candidates may not actually lead to a faster development or regulatory review or approval process; the inability to obtain orphan drug exclusivity for drug candidates; failure to obtain marketing approval in international jurisdictions; any post-marketing restrictions or withdrawals from the market; effects of recently enacted and future legislation; failure to comply with environmental, health and safety laws and regulations; failure to achieve market acceptance by physicians, patients, or third-party payors; failure to establish effective sales, marketing and distribution capabilities or enter into agreements with third parties with such capabilities; effects of substantial competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to retain key executives and attract, retain and motivate qualified personnel; difficulties in managing the Company's growth; risks associated with operating internationally, including the possibility of sanctions with respect to our operations in Russia; the possibility of system failures or security breaches; failure to obtain and maintain patent protection for or otherwise protect our technology and products; effects of patent or other intellectual property lawsuits; the price of our common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company; and any securities class action litigation. These and other important factors discussed under the caption "Risk Factors" in BIND's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 9, 2016, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause the companies' views to change. These forward-looking statements should not be relied upon as representing the companies' views as of any date subsequent to the date of this press release.
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced the publication of detailed methods for its hydrophobic ion pairing (HIP) approach that can be applied to a wide range of ionizable molecules, greatly increasing the diversity of payloads that can be encapsulated in ACCURINS®. Previous data demonstrated the potential of ACCURINS® to deliver the aurora B kinase inhibitor AZD2811 to tumor sites and in this publication, researchers from BIND Therapeutics and AstraZeneca describe the preparation of nanoparticles encapsulating AZD2811 in detail and characterize their pharmacokinetics, tolerability and mechanisms of tumor growth inhibition in preclinical models. The data are published in the May 10, 2016 issue of the Journal of Controlled Release. "In addition to the aurora B kinase inhibitor AZD2811, the HIP approach can be applied to additional therapeutic payloads with the ACCURINS® platform," said Jonathan Yingling, Ph.D., chief scientific officer at BIND Therapeutics. "Highly charged molecules, such as oligonucleotides, and small molecules with therapeutic potential but where development has been constrained by on-target systemic toxicities, can now be optimized for controlled release in diseased tissue with our HIP technology. When coupled with the targeting ligand component of ACCURINS® to elicit a biological response and enhance disease tissue accumulation, powerful therapeutic synergies can be created within a single particle." In the paper titled "A novel in situ hydrophobic ion pairing formulation strategy for clinical product selection of a nanoparticle drug delivery system," researchers describe a technique using counterions of varying physico-chemical properties to optimize AZD2811 drug loading and release kinetics in ACCURINS® without changing the chemical structure of the active pharmaceutical ingredient (API) or properties of the polymer that make up the particle. In addition to describing the production and characteristics of a library of AZD2811 formulations using hydrophobic ion pairing, the article also provides preclinical efficacy and tolerability data for AZD2811 as well as detailed pharmaceutical characterization and mechanistic studies related to the HIP approach. AZD2811 is currently being evaluated in a phase 1 clinical trial in patients with solid tumors. "Utilising the HIP approach, the drug loading and release kinetics of AZD2811 could be optimised to improve the therapeutic index of an important candidate drug, enable practical dosing in the clinic and further clinical development in oncology, said Marianne Ashford, principal scientist drug targeting, pharmaceutical sciences at AstraZeneca.